Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

ABSTRACT Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lisa K. McNeil, Robert G. K. Donald, Alexey Gribenko, Roger French, Nathaniel Lambert, Shannon L. Harris, Thomas R. Jones, Sheng Li, Gary Zlotnick, Ulrich Vogel, Heike Claus, Raquel Abad, Julio A. Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A. Caugant, Paula Kriz, Martin Musilek, Xin Wang, Jeni Vuong, Leonard W. Mayer, Michael W. Pride, Kathrin U. Jansen, Annaliesa S. Anderson
Format: article
Langue:EN
Publié: American Society for Microbiology 2018
Sujets:
meningococcal antigen surface expression (MEASURE) assay
Neisseria meningitidis serogroup B
factor H binding protein
flow cytometry
vaccine
Microbiology
QR1-502
Accès en ligne:https://doaj.org/article/c3d0bb482f1f4b6d8d47c0ace63109e3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/c3d0bb482f1f4b6d8d47c0ace63109e3

Documents similaires